Compare Becton Dickinson and Co (BDX) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Intel Corp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Intel Corp trades at $111.5 (market cap $541.60B). The key difference: Intel Corp is far larger — about 13× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | INTC | |
|---|---|---|
Market Cap | $41.51B | $541.60B |
Sector | Health | Technology |
52-Week High | $185.39 | $140.94 |
52-Week Low | $135.49 | $19.31 |
Enterprise Value | $57.97B | $553.84B |
Dividend Yield | 2.79% | 2.24% |
Volume | — | 43,552,012 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Intel (INTC) trades at $103.12, down 6.12% today, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with negative net income margins and high valuation ratios, though operating cash flow remains strong at $9.7 billion. Recent news highlights Intel's $5.7 billion AI investment in Ireland while analysts express caution about near-term challenges in the semiconductor sector.
Intel presents a complex investment case with improving operational trends but persistent profitability challenges. The stock offers potential upside to the $105.48 consensus target but faces headwinds from competitive pressures and high capital expenditures. Key catalysts include AI execution and PC market recovery, while risks include margin compression and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
